Cefiderocol: A Siderophore Cephalosporin

The Annals of Pharmacotherapy
Rania M El-Lababidi, John George Rizk

Abstract

This article reviews the available data on the chemistry, spectrum of activity, pharmacokinetic and pharmacodynamic properties, clinical efficacy, and potential place in therapy of cefiderocol. A literature search through PubMed, Google Scholar, and ClinicalTrials.gov was conducted (2009 to March 2020) using the search terms cefiderocol and S-649266. Abstracts presented at recent conferences, prescribing information, and information from the US Food and Drug Administration (FDA) and the manufacturer's website were reviewed. All relevant published articles, package inserts, and unpublished meeting abstracts on cefiderocol were reviewed. Cefiderocol is the first siderophore antibiotic to be approved by the FDA. It was shown to be active against a wide range of resistant Gram-negative pathogens, including multidrug-resistant (MDR) Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacteriaceae, and Stenotrophomonas maltophilia. Cefiderocol was studied in the treatment of adult patients with complicated urinary tract infections (cUTIs) and nosocomial pneumonia and was well tolerated. In a recently completed prospective study, higher mortality was observed with cefiderocol in the treatment of serious infections caused by carbape...Continue Reading

References

Nov 1, 1982·The Journal of Antimicrobial Chemotherapy·G L Dunn
Aug 1, 1980·The Journal of Cell Biology·F D Warner, N C Zanetti
Nov 1, 1993·The Journal of Antimicrobial Chemotherapy·G G Grassi, C Grassi
Feb 23, 2008·The Lancet Infectious Diseases·Johann D D Pitout, Kevin B Laupland
Feb 14, 2009·Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine·Ute MöllmannDorothe Ankel-Fuchs
Mar 24, 2010·Antimicrobial Agents and Chemotherapy·Malcolm G P PageEric Desarbre
Mar 8, 2012·Future Medicinal Chemistry·Cheng JiMarvin J Miller
Jul 23, 2013·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·C GlasnerUNKNOWN European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group
Sep 5, 2013·The Journal of Antibiotics·Mark S ButlerMatthew A Cooper
Aug 12, 2014·Trends in Pharmacological Sciences·Agnieszka GórskaMichał Piotr Marszałł
Mar 12, 2015·Environmental Science and Pollution Research International·Maumita SahaProsun Tribedi
Aug 12, 2015·Annals of Intensive Care·Étienne RuppéFrançois Barbier
May 4, 2016·Antimicrobial Agents and Chemotherapy·Tsukasa Ito-HoriyamaKazuhiro Tateda
Apr 4, 2017·The Journal of Antimicrobial Chemotherapy·Matthew E FalagasUNKNOWN Hellenic Cefiderocol Study Group
Jul 28, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J DobiasP Nordmann
Oct 25, 2017·Antimicrobial Agents and Chemotherapy·Akinobu ItoYoshinori Yamano
Apr 9, 2018·European Journal of Clinical Pharmacology·Takayuki KatsubeToshihiro Wajima
Nov 13, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jonathan D EdgeworthRichard Beale
Jun 21, 2019·The Journal of Antimicrobial Chemotherapy·Takayuki KatsubeHidetoshi Furuie
Aug 6, 2019·Clinical Therapeutics·Carlos SanabriaTsutae Den Nagata
Oct 30, 2019·Antimicrobial Agents and Chemotherapy·James M KiddDavid P Nicolau
Nov 15, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Takafumi Sato, Kenji Yamawaki

❮ Previous
Next ❯

Citations

Jun 26, 2021·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Kathleen Tompkins, David van Duin
Jul 3, 2021·Infection and Drug Resistance·Zhan-Jie LiWei-Hong Zhang
Aug 23, 2021·Clinical Pharmacokinetics·Muhammad BilalMax Taubert

❮ Previous
Next ❯

Software Mentioned

PRISMA
SIDERO
Google Scholar

Related Concepts

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.